GLP-1 Side Effects and How to Manage Them
Nausea, constipation, fatigue — the most common GLP-1 side effects are predictable, time-limited, and largely manageable with the right protocol.
Most patients starting semaglutide or tirzepatide will experience some side effects in the first weeks. They are almost always dose-dependent, time-limited, and treatable — and they are rarely a reason to stop therapy.
The pattern most patients follow
The first 48–72 hours after a dose increase produce the most pronounced symptoms: mild nausea, early satiety, sometimes a slight headache or fatigue. These typically fade as your body adapts to the new dose, which is why GLP-1 protocols escalate gradually rather than starting at the therapeutic dose.
Nausea
The most common complaint. Eat smaller, lower-fat meals; stop eating at the first signal of fullness; avoid alcohol around dose day; stay hydrated. If nausea is interfering with daily life, your physician can slow your titration or add an as-needed antiemetic.
Constipation
GLP-1 medications slow gut motility — that is part of how they work. Fluid (2.5–3 L per day), daily fiber, magnesium citrate, and regular movement resolve this for most patients. Persistent constipation should be reported to your clinician.
Fatigue and "GLP-1 brain"
Often a sign of dropping calories too quickly. The medication suppresses appetite, but you still need adequate protein (1.0–1.2 g/kg of goal body weight) and electrolytes to maintain energy and protect muscle.
When to call your physician
Severe abdominal pain radiating to the back, persistent vomiting, signs of dehydration, or symptoms of gallbladder disease are not normal and warrant immediate clinical evaluation.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.— New England Journal of Medicine, 2021.
- 2.Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.— New England Journal of Medicine, 2022.
- 3.FDA Prescribing Information: Wegovy (semaglutide) injection.— U.S. Food and Drug Administration, 2021.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
